{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:04:59Z","timestamp":1778043899503,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100030993","name":"Universit\u00e0 della Svizzera italiana","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030993","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a common disease, which was previously approached with sinus surgery or systemic corticosteroids. The advent of biological therapies radically changed the approach to this disease. On the other hand, there is scarce scientific evidence of how specific subsets of patients respond to this treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>this is a monocentric, prospective study investigating the long-term efficacy on biweekly 300\u00a0mg dupilumab therapy in CRSwNP, prescribed to 61 patients. Patients were evaluated at baseline and every 2\u00a0months for the first 6\u00a0months, then at 9, 12, 16, 20 and 24\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>dupilumab proved to be an effective treatment, neatly improving both subjective and objective measurements in CRSwNP. The main finding of the study is the difference between specific subgroups of patients: while the overall response is similar, patients with Th2 comorbidities such as asthma and atopy tend to reach a stable response later, with the improvement ongoing even after 6\u00a0months of therapy, while non-asthmatic, non-atopic patients attain an earlier stability in response.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>dupilumab provides an excellent long-term control of CRSwNP, but the response in asthmatic and atopic patients appears to be different and delayed when compared to non asthmatic and non atopic ones.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00405-024-08738-2","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T09:02:07Z","timestamp":1717837327000},"page":"5285-5292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dupilumab: a delayed response in asthmatic and atopic patients treated for chronic rhinosinusitis with nasal polyps"],"prefix":"10.1007","volume":"281","author":[{"given":"Umberto","family":"Tanzini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rampi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Vinciguerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Dan\u00e8","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona Rita","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Bussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-3484","authenticated-orcid":false,"given":"Matteo","family":"Trimarchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,8]]},"reference":[{"key":"8738_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"Suppl 29","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ et al (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinol J Suppl 29:1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600","journal-title":"Rhinol J"},{"issue":"3","key":"8738_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5935\/1808-8694.20130055","volume":"79","author":"JG Mascarenhas","year":"2013","unstructured":"Mascarenhas JG et al (2013) Long-term outcomes of endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyps. Braz J Otorhinolaryngol 79(3):306\u2013311. https:\/\/doi.org\/10.5935\/1808-8694.20130055","journal-title":"Braz J Otorhinolaryngol"},{"issue":"2","key":"8738_CR3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s11882-012-0329-5","volume":"13","author":"BE Howard","year":"2013","unstructured":"Howard BE, Lal D (2013) Oral steroid therapy in chronic rhinosinusitis with and without nasal polyposis. Curr Allergy Asthma Rep 13(2):236\u2013243. https:\/\/doi.org\/10.1007\/s11882-012-0329-5","journal-title":"Curr Allergy Asthma Rep"},{"issue":"10209","key":"8738_CR4","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","volume":"394","author":"C Bachert","year":"2019","unstructured":"Bachert C et al (2019) Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 394(10209):1638\u20131650. https:\/\/doi.org\/10.1016\/S0140-6736(19)31881-1","journal-title":"Lancet"},{"issue":"10","key":"8738_CR5","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","volume":"9","author":"JK Han","year":"2021","unstructured":"Han JK et al (2021) Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 9(10):1141\u20131153. https:\/\/doi.org\/10.1016\/S2213-2600(21)00097-7","journal-title":"Lancet Respir Med"},{"issue":"3","key":"8738_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P et al (2020) Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 146(3):595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"8738_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.10698","volume":"22","author":"A Fildan","year":"2021","unstructured":"Fildan A et al (2021) Biological therapies targeting the type 2 inflammatory pathway in severe asthma (Review). Exp Ther Med 22(5):1\u201311. https:\/\/doi.org\/10.3892\/etm.2021.10698","journal-title":"Exp Ther Med"},{"issue":"3","key":"8738_CR8","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","volume":"9","author":"TM Laidlaw","year":"2021","unstructured":"Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP (2021) Chronic rhinosinusitis with nasal polyps and asthma. J Allergy Clin Immunol Pract 9(3):1133\u20131141. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.063","journal-title":"J Allergy Clin Immunol Pract"},{"key":"8738_CR9","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/S0194-5998(97)70005-6","volume":"117","author":"VJ Lund","year":"1997","unstructured":"Lund VJ, Kennedy DW (1997) Staging for rhinosinusitis. Otolaryngol-Head Neck Surg 117:S35\u2013S40. https:\/\/doi.org\/10.1016\/S0194-5998(97)70005-6","journal-title":"Otolaryngol-Head Neck Surg"},{"key":"8738_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-022-07389-5","author":"A Vinciguerra","year":"2022","unstructured":"Vinciguerra A et al (2022) Hypereosinophilia management in patients with type 2 chronic rhinosinusitis treated with dupilumab: preliminary results. Eur Arch Otorhinolaryngol. https:\/\/doi.org\/10.1007\/s00405-022-07389-5","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"8738_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/alr.23212","author":"A Rampi","year":"2023","unstructured":"Rampi A et al (2023) Early increase in eosinophil count may predict long-term hypereosinophilia during dupilumab treatment: a 2 year observational study. Int Forum Allergy Rhinol. https:\/\/doi.org\/10.1002\/alr.23212","journal-title":"Int Forum Allergy Rhinol"},{"issue":"6","key":"8738_CR12","doi-asserted-by":"publisher","first-page":"538","DOI":"10.14639\/0392-100X-N2156","volume":"42","author":"M Trimarchi","year":"2022","unstructured":"Trimarchi M et al (2022) A prospective study on the efficacy of dupilumab in chronic rhinosinusitis with type 2 inflammation. Acta Otorhinolaryngol Ital 42(6):538\u2013544. https:\/\/doi.org\/10.14639\/0392-100X-N2156","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"8738_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102684","author":"E De Corso","year":"2022","unstructured":"De Corso E et al (2022) Effectiveness of dupilumab in the treatment of patients with severe uncontrolled CRSwNP: a \u2018real-life\u2019 observational study in the first year of treatment. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11102684","journal-title":"J Clin Med"},{"issue":"1","key":"8738_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12948-015-0026-8","volume":"13","author":"MR Yacoub","year":"2015","unstructured":"Yacoub MR et al (2015) Are atopy and eosinophilic bronchial inflammation associated with relapsing forms of chronic rhinosinusitis with nasal polyps? Clin Mol Allergy 13(1):1\u20136. https:\/\/doi.org\/10.1186\/s12948-015-0026-8","journal-title":"Clin Mol Allergy"},{"issue":"6","key":"8738_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1177\/014556131509400608","volume":"94","author":"M Farhadi","year":"2015","unstructured":"Farhadi M, Barati M, Tabatabaii A, Shekarabi M, Noorbakhsh S, Javadinia S (2015) Th1 and Th2 cytokine gene expression in atopic and nonatopic patients with nasal polyposis. Ear Nose Throat J 94(6):228\u2013235. https:\/\/doi.org\/10.1177\/014556131509400608","journal-title":"Ear Nose Throat J"},{"issue":"5","key":"8738_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.aller.2013.06.007","volume":"42","author":"M Nabavi","year":"2014","unstructured":"Nabavi M et al (2014) Increased level of interleukin-13, but not interleukin-4 and interferon-\u03b3 in chronic rhinosinusitis with nasal polyps. Allergol Immunopathol 42(5):465\u2013471. https:\/\/doi.org\/10.1016\/j.aller.2013.06.007","journal-title":"Allergol Immunopathol"},{"key":"8738_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5753524","author":"JM Escamilla-Gil","year":"2022","unstructured":"Escamilla-Gil JM, Fernandez-Nieto M, Acevedo N (2022) Understanding the cellular sources of the fractional exhaled nitric oxide (FeNO) and its role as a biomarker of type 2 inflammation in asthma. Biomed Res Int. https:\/\/doi.org\/10.1155\/2022\/5753524","journal-title":"Biomed Res Int"},{"issue":"5","key":"8738_CR18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1055\/s-0042-1743290","volume":"43","author":"L Loewenthal","year":"2022","unstructured":"Loewenthal L, Menzies-Gow A (2022) FeNO in asthma. Semin Respir Crit Care Med 43(5):635\u2013645. https:\/\/doi.org\/10.1055\/s-0042-1743290","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"8738_CR19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00405-022-07634-x","volume":"280","author":"A Rampi","year":"2023","unstructured":"Rampi A, Vinciguerra A, Tanzini U, Bussi M, Trimarchi M (2023) Comparison of guidelines for prescription and follow-up of biologics for chronic rhinosinusitis with nasal polyps. Eur Arch Otorhinolaryngol 280(1):39\u201346. https:\/\/doi.org\/10.1007\/s00405-022-07634-x","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"8738_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/all.15772","author":"E De Corso","year":"2023","unstructured":"De Corso E et al (2023) Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational Phase IV real-life study (DUPIREAL). Allergy Eur J Allergy Clin Immunol. https:\/\/doi.org\/10.1111\/all.15772","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"issue":"12","key":"8738_CR21","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11882-023-01114-w","volume":"23","author":"C-L Guo","year":"2023","unstructured":"Guo C-L et al (2023) Type 2 biomarkers for the indication and response to biologics in CRSwNP. Curr Allergy Asthma Rep 23(12):703\u2013713. https:\/\/doi.org\/10.1007\/s11882-023-01114-w","journal-title":"Curr Allergy Asthma Rep"},{"issue":"45","key":"8738_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000031031","volume":"101","author":"M Bertlich","year":"2022","unstructured":"Bertlich M et al (2022) Subgroups in the treatment of nasal polyposis with dupilumab: a retrospective study. Medicine 101(45):e31031. https:\/\/doi.org\/10.1097\/MD.0000000000031031","journal-title":"Medicine"},{"key":"8738_CR23","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin22.489","author":"WJ Fokkens","year":"2023","unstructured":"Fokkens WJ et al (2023) EPOS\/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinol J. https:\/\/doi.org\/10.4193\/Rhin22.489","journal-title":"Rhinol J"},{"issue":"1","key":"8738_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","volume":"147","author":"C Bachert","year":"2021","unstructured":"Bachert C et al (2021) EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management. J Allergy Clin Immunol 147(1):29\u201336. https:\/\/doi.org\/10.1016\/j.jaci.2020.11.013","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"8738_CR25","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1002\/ccr3.3792","volume":"9","author":"M Trimarchi","year":"2021","unstructured":"Trimarchi M, Indelicato P, Vinciguerra A, Bussi M (2021) Clinical efficacy of dupilumab in the treatment of severe chronic rhinosinusitis: the first case outside of a clinical trial. Clin Case Rep 9(3):1428\u20131432. https:\/\/doi.org\/10.1002\/ccr3.3792","journal-title":"Clin Case Rep"},{"issue":"10","key":"8738_CR26","doi-asserted-by":"publisher","first-page":"100592","DOI":"10.1016\/j.waojou.2021.100592","volume":"14","author":"C Lombardi","year":"2021","unstructured":"Lombardi C et al (2021) ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments. World Allergy Organ J 14(10):100592. https:\/\/doi.org\/10.1016\/j.waojou.2021.100592","journal-title":"World Allergy Organ J"},{"issue":"5","key":"8738_CR27","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.2500\/ajra.2013.27.3950","volume":"27","author":"FC Marcela","year":"2013","unstructured":"Marcela FC, Macdonald KI, Lee J, Witterick IJ (2013) The use of postoperative topical corticosteroids in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis. Am J Rhinol Allergy 27(5):e146\u2013e157. https:\/\/doi.org\/10.2500\/ajra.2013.27.3950","journal-title":"Am J Rhinol Allergy"},{"issue":"12","key":"8738_CR28","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.1007\/s00405-022-07470-z","volume":"279","author":"SC Gomes","year":"2022","unstructured":"Gomes SC et al (2022) Reboot surgery for chronic rhinosinusitis with nasal polyposis: recurrence and smell kinetics. Eur Arch Otorhinolaryngol 279(12):5691\u20135699. https:\/\/doi.org\/10.1007\/s00405-022-07470-z","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"8738_CR29","unstructured":"Vaira LA et al (2021) The Amsterdam Classification of Completeness of Endoscopic Sinus Surgery (ACCESS): a new CT-based scoring system grading the extent of surgery"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08738-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-024-08738-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-024-08738-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T20:16:32Z","timestamp":1726949792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-024-08738-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,8]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["8738"],"URL":"https:\/\/doi.org\/10.1007\/s00405-024-08738-2","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,8]]},"assertion":[{"value":"9 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from each patient for treatment and use of de-identified clinical data for study purposes; the study was approved by the institutional review board (IRB) of San Raffaele Hospital (Comitato Etico Ospedale San Raffaele, 112\/INT\/2021), and conducted according to the ethical standards established in the 1964 Declaration of Helsinki, as revised in 2013.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"MT declares honoraria as a speaker from Sanofi, Glaxo-Smith and Kline and Novartis. GD declares honoraria as a speaker from Sanofi, Glaxo-Smith and Kline. The other authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}